Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix Immunogenicity and Safety in Healthy Females (18-35)
NCT00306241Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2006
- Primary completion
- Jun 2007
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection and Cervical Cancer (CC), sponsored by GSK. Primary endpoint: Seroconversion rates to HPV-16 and HPV-18 at 7 months. Started Mar 2006; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NCT00306241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306241.